Tech Company Financing Transactions
Presage Biosciences Funding Round
On 7/18/2018, Presage Biosciences received $6 million in Series D funding from Celgene and Takeda Ventures.
Transaction Overview
Company Name
Announced On
7/18/2018
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series D
Investors
Proceeds Purpose
This financing allows us to expand our clinical operation and advance the design of our current device to reach a wider array of solid tumors.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
530 Fairview Ave. North 1000
Seattle, WA 98109
USA
Seattle, WA 98109
USA
Phone
Website
Email Address
Overview
Presage Biosciences was founded in November, 2008 based on technology invented in the laboratory of Dr. James Olson, a pediatric oncologist focused on brain tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Klinghoffer
Vice President
Kirsten Anderson
VP - Operations
Jon Williams
VP - R & D
John Streeter
Browse more venture capital transactions:
Prev: 7/18/2018: Perch Interactive venture capital transaction
Next: 7/18/2018: CyberMDX venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs